Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...

Refugees tend to work hard, are loyal to their employers and often are more willing to relocate than other hires because they ...

Pfizer will end global development of its bleeding disorder gene therapy, Beqvez, the Nikkei reported on Thursday.

An intriguing battle is brewing in the market to treat patients with transthyretin amyloid cardiomyopathy (ATTR-CM). | BridgeBio reported that 1,028 unique prescriptions have been written by 516 ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

The Make America Healthy Again commission is taking action on mRNA vaccines as several states consider legislation to ban ...

Researchers identify a new player in human immunity that can go rogue and turn the immune system against the body’s own ...

Pfizer (NYSE: PFE) has hit a bit of a rough patch, after doing well with its COVID vaccine and Paxlovid treatment. The ...

Baby boomers looking to set up their portfolios for a relaxing and rewarding retirement have plenty of factors to consider.

Ambrosia Biosciences Inc., a drug-discovery company launched last year, has added Jason Haddock, a former executive with ArcherDX Inc. and Array BioPharma Inc., to its board of directors.